Cemiplimab Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Cemiplimab comprises 152 peer-reviewed publications across 15 journals, 2 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Neoplasms, Adrenocortical Carcinoma, Carcinoma, Non-Small-Cell Lung, and Melanoma. Most recent publication: Longitudinal DCE MRI Vascular Textures: Radiologic and Biologic Insights for pCR Prediction in HER2-Negative Breast Cancer., Radiol Artif Intell, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
    Tawbi HA, Schadendorf D, Lipson EJ, et al. · N Engl J Med · 2022
    PubMed: PMID 34986285 · NCT06887088 (ENCEFALO) · Melanoma
  2. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study.
    Tawbi HA, Forsyth PA, Hodi FS, et al. · Lancet Oncol · 2022
    PubMed: PMID 34774225 · NCT06887088 (ENCEFALO) · Melanoma
  3. Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study).
    Márquez-Rodas I, Álvarez A, Arance A, et al. · Neuro Oncol · 2024
    PubMed: PMID 38946469 · NCT06887088 (ENCEFALO) · Melanoma
  4. An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis.
    LaMarche NM, Hegde S, Park MD, et al. · Nature · 2024
    PubMed: PMID 38057662 · NCT06743581 (Dupi-Cemi) · Carcinoma, Non-Small-Cell Lung
  5. Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma.
    Hamid O, Lewis KD, Weise A, et al. · J Clin Oncol · 2024
    PubMed: PMID 38900987 · NCT06887088 (ENCEFALO) · Melanoma
  6. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.
    Davies MA, Saiag P, Robert C, et al. · Lancet Oncol · 2017
    PubMed: PMID 28592387 · NCT06887088 (ENCEFALO) · Melanoma
  7. A Phase I, First-in-Human, Dose-Escalation, Expansion Trial of Cytokine-Encoding Synthetic mRNA Mixture Alone or with Cemiplimab in Advanced Solid Tumors.
    Bechter O, Loquai C, Champiat S, et al. · Clin Cancer Res · 2025
    PubMed: PMID 40152791 · NCT03871348 · Neoplasm Metastasis
  8. Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study.
    Baranda JC, Robbrecht D, Sullivan R, et al. · Clin Transl Sci · 2024
    PubMed: PMID 38898592 · NCT03192345

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT03257267Neoplasm MetastasisOverall Survival (OS)
From first dose up to 90 following last dose (~42 months)
Cemiplimab11.7 Months
Investigator Choice (IC) Chemotherapy8.5 Months
NCT03257267Neoplasm MetastasisOverall Survival (OS) in the SCC Population
From first dose up to 90 following last dose (~42 months)
Cemiplimab10.9 Months
Investigator Choice (IC) Chemotherapy8.8 Months

Publications by year

1990–2026: 152 publications.

1990
1
1992
1
2000
1
2002
1
2004
1
2005
1
2006
1
2009
4
2010
2
2011
1
2012
5
2013
1
2016
3
2017
2
2018
6
2019
3
2020
12
2021
23
2022
28
2023
14
2024
19
2025
15
2026
7

Publications by indication

Neoplasms (35)

  • Longitudinal DCE MRI Vascular Textures: Radiologic and Biologic Insights for pCR Prediction in HER2-Negative Breast Cancer.
    Radiol Artif Intell · 2026 · PMID 41879562 · NCT01042379
  • Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
    NPJ Breast Cancer · 2026 · PMID 36456573 · NCT01042379
  • Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial.
    Front Oncol · 2026 · PMID 40777112 · NCT01042379
  • Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial.
    JCO Precis Oncol · 2025 · PMID 40526879 · NCT01042379
  • Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.
    Breast Cancer Res Treat · 2025 · PMID 39625569 · NCT01042379

Adrenocortical Carcinoma (15)

  • Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up.
    J Clin Oncol · 2023 · PMID 37071838 · NCT07085572
  • Advances in adrenocortical carcinoma pharmacotherapy: what is the current state of the art?
    Expert Opin Pharmacother · 2022 · PMID 35876101 · NCT07085572
  • Phase 2 study of pembrolizumab in patients with advanced rare cancers.
    J Immunother Cancer · 2021 · PMID 32188704 · NCT07085572
  • Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies.
    Cancer · 2021 · PMID 33216356 · NCT07085572
  • Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538.
    Oncoimmunology · 2021 · PMID 33889439 · NCT07085572

Carcinoma, Non-Small-Cell Lung (12)

  • Alirocumab plus cemiplimab in advanced immuno-refractory metastatic non-small cell lung cancer: an ongoing multi-center phase II study.
    Future Oncol · 2026 · PMID 41940540 · NCT05553834
  • Review of patient-reported outcomes in EMPOWER-Lung 1 in patients with advanced non-small cell lung cancer treated with cemiplimab versus chemotherapy.
    Cancer · 2026 · PMID 41808570 · NCT03088540
  • Clinical Interchangeability of PD-L1 Immunohistochemistry Assays in First-Line Non-Small Cell Lung Cancer Management With Cemiplimab.
    JCO Precis Oncol · 2025 · PMID 40991883 · NCT03088540
  • Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: first-in-human Phase 1 trial.
    Nat Commun · 2025 · PMID 41022754 · NCT06171750
  • Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1.
    J Thorac Oncol · 2025 · PMID 40118215 · NCT03088540

Melanoma (11)

  • Next-Generation Immune Checkpoints and Tumor Microenvironment Modulation in Cancer Immunotherapy.
    J Immunol Res · 2026 · PMID 41811823 · NCT05352672
  • Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors.
    J Immunother Cancer · 2025 · PMID 40713179 · NCT03684785
  • Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study).
    Neuro Oncol · 2024 · PMID 38946469 · NCT06887088
  • Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma.
    J Clin Oncol · 2024 · PMID 38900987 · NCT06887088
  • Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
    N Engl J Med · 2022 · PMID 34986285 · NCT06887088

Carcinoma, Basal Cell (7)

  • CASE (CemiplimAb-rwlc Survivorship and Epidemiology): a study in advanced basal cell carcinoma.
    Future Oncol · 2025 · PMID 39797702 · NCT03836105
  • Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up.
    J Am Acad Dermatol · 2024 · PMID 37839734 · NCT03132636
  • Quality of life in cemiplimab-treated patients with locally advanced basal cell carcinoma in a Phase II clinical trial.
    Future Oncol · 2024 · PMID 39073799 · NCT03132636
  • Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors.
    Ann Oncol · 2024 · PMID 38072158 · NCT03132636
  • Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
    Lancet Oncol · 2021 · PMID 34000246 · NCT03132636

Neoplasm Metastasis (4)

  • A Phase I, First-in-Human, Dose-Escalation, Expansion Trial of Cytokine-Encoding Synthetic mRNA Mixture Alone or with Cemiplimab in Advanced Solid Tumors.
    Clin Cancer Res · 2025 · PMID 40152791 · NCT03871348
  • Survival with Cemiplimab in Recurrent Cervical Cancer.
    N Engl J Med · 2022 · PMID 35139273 · NCT03257267
  • EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer.
    Eur J Cancer · 2022 · PMID 35922251 · NCT03257267
  • SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer.
    JCI Insight · 2022 · PMID 34375311 · NCT06790602

Publications by journal

Trial-results highlights

In the NCT03257267 study, which evaluated patients with neoplasm metastasis, the primary outcome measured was Overall Survival (OS). This endpoint tracked survival from the first dose up to 90 days following the last dose, spanning approximately 42 months. In this trial, the Cemiplimab arm reported a median Overall Survival of 11.7 Months. For comparison, the Investigator Choice (IC) Chemotherapy arm in the same study reported a median Overall Survival of 8.5 Months.

Within the same NCT03257267 study, Overall Survival was also specifically evaluated in the Squamous Cell Carcinoma (SCC) population. For these patients, tracking survival from the first dose up to 90 days following the last dose (approximately 42 months), the Cemiplimab arm reported a median Overall Survival of 10.9 Months. The Investigator Choice (IC) Chemotherapy arm for the SCC population in this trial reported a median Overall Survival of 8.8 Months.

All values presented are sourced from primary clinical trial registry reporting. For comprehensive clinical decisions, individual published papers and detailed study reports should be consulted.

All Cemiplimab publications (152)

2026 (7 papers)

  1. Longitudinal DCE MRI Vascular Textures: Radiologic and Biologic Insights for pCR Prediction in HER2-Negative Breast Cancer.
    Teng X, Ma J, Zhang J, et al. · Radiol Artif Intell · 2026 · Derived
    PubMed: PMID 41879562 · NCT01042379 (I-SPY) · Neoplasms
  2. Alirocumab plus cemiplimab in advanced immuno-refractory metastatic non-small cell lung cancer: an ongoing multi-center phase II study.
    Oduah EI, Zhang T, Jung SH, et al. · Future Oncol · 2026 · Derived
    PubMed: PMID 41940540 · NCT05553834 · Carcinoma, Non-Small-Cell Lung
  3. Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
    Lang JE, Forero-Torres A, Yee D, et al. · NPJ Breast Cancer · 2026 · Derived
    PubMed: PMID 36456573 · NCT01042379 (I-SPY) · Neoplasms
  4. Androgen deprivation, androgen receptor-targeted vaccination, and nivolumab in patients with high-risk localized prostate cancer.
    Jarrard D, Eickhoff J, Kyriakopoulos CE, et al. · J Immunother Cancer · 2026 · Derived
    PubMed: PMID 41781018 · NCT04989946 · Prostatic Neoplasms
  5. Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial.
    Hensley M, Lengfeld J, Stoesz S, et al. · Front Oncol · 2026 · Derived
    PubMed: PMID 40777112 · NCT01042379 (I-SPY) · Neoplasms
  6. Review of patient-reported outcomes in EMPOWER-Lung 1 in patients with advanced non-small cell lung cancer treated with cemiplimab versus chemotherapy.
    Gandara DR, Gümüş M, Kilickap S, et al. · Cancer · 2026 · Derived
    PubMed: PMID 41808570 · NCT03088540 · Carcinoma, Non-Small-Cell Lung
  7. Next-Generation Immune Checkpoints and Tumor Microenvironment Modulation in Cancer Immunotherapy.
    Bautista J, Echeverría CE, Maldonado-Noboa I, et al. · J Immunol Res · 2026 · Derived
    PubMed: PMID 41811823 · NCT05352672 · Melanoma

2025 (15 papers)

  1. A Phase I, First-in-Human, Dose-Escalation, Expansion Trial of Cytokine-Encoding Synthetic mRNA Mixture Alone or with Cemiplimab in Advanced Solid Tumors.
    Bechter O, Loquai C, Champiat S, et al. · Clin Cancer Res · 2025 · Trial result
    PubMed: PMID 40152791 · NCT03871348 · Neoplasm Metastasis
  2. Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial.
    Wolf DM, Yau C, Campbell M, et al. · JCO Precis Oncol · 2025 · Derived
    PubMed: PMID 40526879 · NCT01042379 (I-SPY) · Neoplasms
  3. Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.
    Rugo HS, Campbell M, Yau C, et al. · Breast Cancer Res Treat · 2025 · Derived
    PubMed: PMID 39625569 · NCT01042379 (I-SPY) · Neoplasms
  4. Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma.
    Rischin D, Porceddu S, Day F, et al. · N Engl J Med · 2025 · Derived
    PubMed: PMID 40454639 · NCT03969004
  5. Clinical Interchangeability of PD-L1 Immunohistochemistry Assays in First-Line Non-Small Cell Lung Cancer Management With Cemiplimab.
    Perez J, Kerr KM, Baker B, et al. · JCO Precis Oncol · 2025 · Derived
    PubMed: PMID 40991883 · NCT03088540 · Carcinoma, Non-Small-Cell Lung
  6. CASE (CemiplimAb-rwlc Survivorship and Epidemiology): a study in advanced basal cell carcinoma.
    Park SJ, Ellison DM, Weight R, et al. · Future Oncol · 2025 · Derived
    PubMed: PMID 39797702 · NCT03836105 (CASE) · Carcinoma, Basal Cell
  7. Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: first-in-human Phase 1 trial.
    Park JC, Curti B, Butler M, et al. · Nat Commun · 2025 · Derived
    PubMed: PMID 41022754 · NCT06171750 (ANCHOR) · Carcinoma, Non-Small-Cell Lung
  8. Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors.
    Milhem MM, Wise-Draper TM, Chandra S, et al. · J Immunother Cancer · 2025 · Derived
    PubMed: PMID 40713179 · NCT03684785 · Melanoma
  9. Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial.
    Leon-Ferre RA, Dimitroff K, Yau C, et al. · Breast Cancer Res · 2025 · Derived
    PubMed: PMID 40551254 · NCT01042379 (I-SPY) · Neoplasms
  10. Efficacy of combined CD38 and PD-1 inhibition with isatuximab and cemiplimab for relapsed/refractory NK/T-cell lymphoma.
    Kim SJ, Lim JQ, Yoon SE, et al. · Blood · 2025 · Derived
    PubMed: PMID 40073374 · NCT04763616 (ICING)
  11. Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1.
    Kilickap S, Baramidze A, Sezer A, et al. · J Thorac Oncol · 2025 · Derived
    PubMed: PMID 40118215 · NCT03088540 · Carcinoma, Non-Small-Cell Lung
  12. A two-stage dual-task learning strategy for early prediction of pathological complete response to neoadjuvant chemotherapy for breast cancer using dynamic contrast-enhanced magnetic resonance images.
    Jing B, Wang J · Phys Med Biol · 2025 · Derived
    PubMed: PMID 40639409 · NCT01042379 (I-SPY) · Neoplasms
  13. Radiomics-based Machine Learning Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Using Physiologically Decomposed Diffusion-weighted MRI.
    Gilad M, Partridge SC, Iima M, et al. · Radiol Imaging Cancer · 2025 · Derived
    PubMed: PMID 40679371 · NCT01042379 (I-SPY) · Neoplasms
  14. Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer.
    Even C, Harrington KJ, Massarelli E, et al. · J Immunother Cancer · 2025 · Derived
    PubMed: PMID 40921630 · NCT03669718 · Squamous Cell Carcinoma of Head and Neck
  15. Mucin 16-Directed Therapy in Pediatric Sarcomas: Case Evidence of Ubamatamab Efficacy in Epithelioid Sarcoma and Its Implications for Other Sarcoma Subtypes.
    Connolly DM, Revon-Rivière G, Chami R, et al. · JCO Precis Oncol · 2025 · Derived
    PubMed: PMID 40749151 · NCT06444880

2024 (19 papers)

  1. Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study).
    Márquez-Rodas I, Álvarez A, Arance A, et al. · Neuro Oncol · 2024 · Trial result
    PubMed: PMID 38946469 · NCT06887088 (ENCEFALO) · Melanoma
  2. An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis.
    LaMarche NM, Hegde S, Park MD, et al. · Nature · 2024 · Trial result
    PubMed: PMID 38057662 · NCT06743581 (Dupi-Cemi) · Carcinoma, Non-Small-Cell Lung
  3. Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma.
    Hamid O, Lewis KD, Weise A, et al. · J Clin Oncol · 2024 · Trial result
    PubMed: PMID 38900987 · NCT06887088 (ENCEFALO) · Melanoma
  4. Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study.
    Baranda JC, Robbrecht D, Sullivan R, et al. · Clin Transl Sci · 2024 · Trial result
    PubMed: PMID 38898592 · NCT03192345
  5. Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors.
    Taylor MH, Naing A, Powderly J, et al. · J Immunother Cancer · 2024 · Derived
    PubMed: PMID 39567210 · NCT05054348
  6. Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up.
    Stratigos AJ, Sekulic A, Peris K, et al. · J Am Acad Dermatol · 2024 · Derived
    PubMed: PMID 37839734 · NCT03132636 · Carcinoma, Basal Cell
  7. Quality of life in cemiplimab-treated patients with locally advanced basal cell carcinoma in a Phase II clinical trial.
    Stratigos AJ, Chen CI, Ivanescu C, et al. · Future Oncol · 2024 · Derived
    PubMed: PMID 39073799 · NCT03132636 · Carcinoma, Basal Cell
  8. Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
    Shatsky RA, Trivedi MS, Yau C, et al. · Nat Med · 2024 · Derived
    PubMed: PMID 39277672 · NCT01042379 (I-SPY) · Neoplasms
  9. High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma.
    Rischin D, Hughes BGM, Basset-Séguin N, et al. · J Immunother Cancer · 2024 · Derived
    PubMed: PMID 38471711 · NCT02760498
  10. Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial.
    Rediti M, Venet D, Joaquin Garcia A, et al. · Nat Commun · 2024 · Derived
    PubMed: PMID 39613746 · NCT01042379 (I-SPY) · Neoplasms
  11. Implementation and impact of an electronic patient reported outcomes system in a phase II multi-site adaptive platform clinical trial for early-stage breast cancer.
    Northrop A, Christofferson A, Umashankar S, et al. · J Am Med Inform Assoc · 2024 · Derived
    PubMed: PMID 39158353 · NCT01042379 (I-SPY) · Neoplasms
  12. Breast Multiparametric MRI for Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer: The BMMR2 Challenge.
    Li W, Partridge SC, Newitt DC, et al. · Radiol Imaging Cancer · 2024 · Derived
    PubMed: PMID 38180338 · NCT01042379 (I-SPY) · Neoplasms
  13. Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors.
    Lewis KD, Peris K, Sekulic A, et al. · Ann Oncol · 2024 · Derived
    PubMed: PMID 38072158 · NCT03132636 · Carcinoma, Basal Cell
  14. Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
    Khoury K, Meisel JL, Yau C, et al. · Nat Med · 2024 · Derived
    PubMed: PMID 39277671 · NCT01042379 (I-SPY) · Neoplasms
  15. Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma.
    Hanna GJ, Dharanesswaran H, Giobbie-Hurder A, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 38252908 · NCT04339062 (CONTRAC)
  16. Safety and Immune Responses Following Anti-PD-1 Monoclonal Antibody Infusions in Healthy Persons With Human Immunodeficiency Virus on Antiretroviral Therapy.
    Gay CL, Bosch RJ, McKhann A, et al. · Open Forum Infect Dis · 2024 · Derived
    PubMed: PMID 38449916 · NCT03787095 · HIV Infections
  17. Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis.
    D'Alessio A, Stefanini B, Blanter J, et al. · Lancet Oncol · 2024 · Derived
    PubMed: PMID 39437804 · NCT03916627 · Carcinoma, Non-Small-Cell Lung
  18. Exploring causes and consequences of early discontinuation of durvalumab after chemoradiotherapy for non-small cell lung cancer.
    Pennock M, Halmos B, Bodner W, et al. · Clin Transl Radiat Oncol · 2024 · Background
    PubMed: PMID 37346274 · NCT06865339 (TRIPL)
  19. Selective Personalized RadioImmunotherapy for Locally Advanced Non-Small-Cell Lung Cancer Trial (SPRINT).
    Ohri N, Jolly S, Cooper BT, et al. · J Clin Oncol · 2024 · Background
    PubMed: PMID 37988638 · NCT06865339 (TRIPL)

2023 (14 papers)

  1. Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial.
    Parker BA, Shatsky RA, Schwab RB, et al. · Breast Cancer Res Treat · 2023 · Derived
    PubMed: PMID 37029329 · NCT01042379 (I-SPY) · Neoplasms
  2. First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.
    Özgüroğlu M, Kilickap S, Sezer A, et al. · Lancet Oncol · 2023 · Derived
    PubMed: PMID 37591293 · NCT03088540 · Carcinoma, Non-Small-Cell Lung
  3. Effect of Longitudinal Variation in Tumor Volume Estimation for MRI-guided Personalization of Breast Cancer Neoadjuvant Treatment.
    Onishi N, Bareng TJ, Gibbs J, et al. · Radiol Imaging Cancer · 2023 · Derived
    PubMed: PMID 37505107 · NCT01042379 (I-SPY) · Neoplasms
  4. Breast Conservation Surgery and Mastectomy Have Similar Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From 1462 Patients on the Prospective, Randomized I-SPY2 Trial.
    Mukhtar RA, Chau H, Woriax H, et al. · Ann Surg · 2023 · Derived
    PubMed: PMID 37325931 · NCT01042379 (I-SPY) · Neoplasms
  5. Nodal peripheral T-cell lymphoma: Chemotherapy-free management, are we there yet?
    Macapagal SC, Bennani NN · Blood Rev · 2023 · Derived
    PubMed: PMID 36898933 · NCT03017820 · Multiple Myeloma
  6. Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study.
    Gross ND, Miller DM, Khushalani NI, et al. · Lancet Oncol · 2023 · Derived
    PubMed: PMID 37875144 · NCT04154943
  7. Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial.
    Gallagher RI, Wulfkuhle J, Wolf DM, et al. · Cell Rep Med · 2023 · Derived
    PubMed: PMID 38086377 · NCT01042379 (I-SPY) · Neoplasms
  8. Onconephrology 2022: An Update.
    Bonilla M, Gudsoorkar P, Wanchoo R, et al. · Kidney360 · 2023 · Derived
    PubMed: PMID 36821617 · NCT04339062 (CONTRAC)
  9. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.
    Wakelee H, Liberman M, Kato T, et al. · N Engl J Med · 2023 · Background
    PubMed: PMID 37272513 · NCT06865339 (TRIPL)
  10. Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.
    Provencio M, Nadal E, González-Larriba JL, et al. · N Engl J Med · 2023 · Background
    PubMed: PMID 37379158 · NCT06865339 (TRIPL)
  11. Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up.
    Powles T, Park SH, Caserta C, et al. · J Clin Oncol · 2023 · Background
    PubMed: PMID 37071838 · NCT07085572 (INTERVAL) · Adrenocortical Carcinoma
  12. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.
    Patel SP, Othus M, Chen Y, et al. · N Engl J Med · 2023 · Background
    PubMed: PMID 36856617 · NCT06865339 (TRIPL)
  13. Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study.
    Girard N, Bar J, Garrido P, et al. · J Thorac Oncol · 2023 · Background
    PubMed: PMID 36307040 · NCT06865339 (TRIPL)
  14. A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma.
    Carlo-Stella C, Zinzani PL, Sureda A, et al. · Hematol Oncol · 2023 · Background
    PubMed: PMID 36251503 · NCT03769181 · Lymphoma

2022 (28 papers)

  1. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
    Tawbi HA, Schadendorf D, Lipson EJ, et al. · N Engl J Med · 2022 · Trial result
    PubMed: PMID 34986285 · NCT06887088 (ENCEFALO) · Melanoma
  2. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study.
    Tawbi HA, Forsyth PA, Hodi FS, et al. · Lancet Oncol · 2022 · Trial result
    PubMed: PMID 34774225 · NCT06887088 (ENCEFALO) · Melanoma
  3. Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES).
    Lau PKH, Feran B, Smith L, et al. · J Immunother Cancer · 2022 · Trial result
    PubMed: PMID 34625515 · NCT06887088 (ENCEFALO) · Melanoma
  4. Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma.
    Cook J, Peng KW, Witzig TE, et al. · Blood Adv · 2022 · Trial result
    PubMed: PMID 35175355 · NCT06508463 · Mycosis Fungoides
  5. Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study.
    Zucali PA, Lin CC, Carthon BC, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 35058326 · NCT03367819 · Carcinoma, Non-Small-Cell Lung
  6. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.
    Wolf DM, Yau C, Wulfkuhle J, et al. · Cancer Cell · 2022 · Derived
    PubMed: PMID 35623341 · NCT01042379 (I-SPY) · Neoplasms
  7. Postneoadjuvant treatment for triple-negative breast cancer.
    Trapani D, Ferraro E, Giugliano F, et al. · Curr Opin Oncol · 2022 · Derived
    PubMed: PMID 35993306 · NCT01042379 (I-SPY) · Neoplasms
  8. Survival with Cemiplimab in Recurrent Cervical Cancer.
    Tewari KS, Monk BJ, Vergote I, et al. · N Engl J Med · 2022 · Derived
    PubMed: PMID 35139273 · NCT03257267 · Neoplasm Metastasis
  9. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.
    Symmans WF, Yau C, Chen YY, et al. · JAMA Oncol · 2022 · Derived
    PubMed: PMID 34529000 · NCT01042379 (I-SPY) · Neoplasms
  10. Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis.
    Rischin D, Khushalani NI, Schmults CD, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 34413166 · NCT02760498
  11. Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial.
    Osdoit M, Yau C, Symmans WF, et al. · JAMA Surg · 2022 · Derived
    PubMed: PMID 36069821 · NCT01042379 (I-SPY) · Neoplasms
  12. EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer.
    Oaknin A, Monk BJ, Vergote I, et al. · Eur J Cancer · 2022 · Derived
    PubMed: PMID 35922251 · NCT03257267 · Neoplasm Metastasis
  13. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.
    Marron TU, Fiel MI, Hamon P, et al. · Lancet Gastroenterol Hepatol · 2022 · Derived
    PubMed: PMID 35065058 · NCT03916627 · Carcinoma, Non-Small-Cell Lung
  14. Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study.
    Gümüş M, Chen CI, Ivanescu C, et al. · Cancer · 2022 · Derived
    PubMed: PMID 36308296 · NCT03088540 · Carcinoma, Non-Small-Cell Lung
  15. Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.
    Gross ND, Miller DM, Khushalani NI, et al. · N Engl J Med · 2022 · Derived
    PubMed: PMID 36094839 · NCT04154943
  16. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck.
    Ferrarotto R, Amit M, Nagarajan P, et al. · Clin Cancer Res · 2022 · Derived
    PubMed: PMID 34187851 · NCT03565783
  17. Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial.
    Chiocca EA, Gelb AB, Chen CC, et al. · Neuro Oncol · 2022 · Derived
    PubMed: PMID 34850166 · NCT04006119 · Glioblastoma
  18. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
    Spigel DR, Faivre-Finn C, Gray JE, et al. · J Clin Oncol · 2022 · Background
    PubMed: PMID 35108059 · NCT06865339 (TRIPL)
  19. Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer.
    Shi AP, Tang XY, Xiong YL, et al. · Front Immunol · 2022 · Background
    PubMed: PMID 35111155 · NCT06865339 (TRIPL)
  20. Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial.
    Laza-Briviesca R, Cruz-Bermúdez A, Nadal E, et al. · Clin Transl Med · 2022 · Background
    PubMed: PMID 34323406 · NCT06865339 (TRIPL)
  21. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial.
    Gogishvili M, Melkadze T, Makharadze T, et al. · Nat Med · 2022 · Background
    PubMed: PMID 36008722 · NCT06865339 (TRIPL)
  22. Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma.
    Gartrell RD, Enzler T, Kim PS, et al. · Oncoimmunology · 2022 · Background
    PubMed: PMID 35558160 · NCT06865339 (TRIPL)
  23. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
    Forde PM, Spicer J, Lu S, et al. · N Engl J Med · 2022 · Background
    PubMed: PMID 35403841 · NCT06865339 (TRIPL)
  24. Advances in adrenocortical carcinoma pharmacotherapy: what is the current state of the art?
    Cremaschi V, Abate A, Cosentini D, et al. · Expert Opin Pharmacother · 2022 · Background
    PubMed: PMID 35876101 · NCT07085572 (INTERVAL) · Adrenocortical Carcinoma
  25. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer.
    Cercek A, Lumish M, Sinopoli J, et al. · N Engl J Med · 2022 · Background
    PubMed: PMID 35660797 · NCT06865339 (TRIPL)
  26. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy.
    Casarrubios M, Provencio M, Nadal E, et al. · J Immunother Cancer · 2022 · Background
    PubMed: PMID 36171009 · NCT06865339 (TRIPL)
  27. SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer.
    Botta GP, Kato S, Patel H, et al. · JCI Insight · 2022 · Background
    PubMed: PMID 34375311 · NCT06790602 (SWITCH) · Neoplasm Metastasis
  28. Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy.
    Andrews LP, Cillo AR, Karapetyan L, et al. · Clin Cancer Res · 2022 · Background
    PubMed: PMID 35579997 · NCT06865339 (TRIPL)

2021 (23 papers)

  1. Suspected Immune-Related Adverse Events With an Anti-PD-1 Inhibitor in Otherwise Healthy People With HIV.
    Gay CL, Bosch RJ, McKhann A, et al. · J Acquir Immune Defic Syndr · 2021 · Trial result
    PubMed: PMID 33929394 · NCT03787095 · HIV Infections
  2. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
    Stratigos AJ, Sekulic A, Peris K, et al. · Lancet Oncol · 2021 · Derived
    PubMed: PMID 34000246 · NCT03132636 · Carcinoma, Basal Cell
  3. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
    Sezer A, Kilickap S, Gümüş M, et al. · Lancet · 2021 · Derived
    PubMed: PMID 33581821 · NCT03088540 · Carcinoma, Non-Small-Cell Lung
  4. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing.
    Rischin D, Migden MR, Lim AM, et al. · J Immunother Cancer · 2021 · Derived
    PubMed: PMID 32554615 · NCT02383212
  5. Atezolizumab in the treatment of metastatic triple-negative breast cancer.
    Pérez-García J, Soberino J, Racca F, et al. · Expert Opin Biol Ther · 2021 · Derived
    PubMed: PMID 32450725 · NCT01042379 (I-SPY) · Neoplasms
  6. Safe Administration of Cemiplimab to a Kidney Transplant Patient with Locally Advanced Squamous Cell Carcinoma of the Scalp.
    Paoluzzi L, Ow TJ · Curr Oncol · 2021 · Derived
    PubMed: PMID 33477979 · NCT04339062 (CONTRAC)
  7. Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis.
    Paccaly AJ, Migden MR, Papadopoulos KP, et al. · Adv Ther · 2021 · Derived
    PubMed: PMID 33768419 · NCT02760498
  8. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
    Nanda R, Liu MC, Yau C, et al. · JAMA Oncol · 2021 · Derived
    PubMed: PMID 32053137 · NCT01042379 (I-SPY) · Neoplasms
  9. Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort.
    Moreno V, Garrido P, Papadopoulos KP, et al. · Lung Cancer · 2021 · Derived
    PubMed: PMID 33831732 · NCT02383212
  10. Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies.
    Kitano S, Shimizu T, Koyama T, et al. · Cancer Chemother Pharmacol · 2021 · Derived
    PubMed: PMID 33146741 · NCT03233139
  11. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.
    I-SPY2 Trial Consortium, Yee D, DeMichele AM, et al. · JAMA Oncol · 2021 · Derived
    PubMed: PMID 32701140 · NCT01042379 (I-SPY) · Neoplasms
  12. Pan-TGFβ inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade.
    Greco R, Qu H, Qu H, et al. · Oncoimmunology · 2021 · Derived
    PubMed: PMID 33224628 · NCT03192345
  13. RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer.
    Engebraaten O, Yau C, Berg K, et al. · Nat Commun · 2021 · Derived
    PubMed: PMID 34741021 · NCT01042379 (I-SPY) · Neoplasms
  14. MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.
    Chien AJ, Tripathy D, Albain KS, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 32031889 · NCT01042379 (I-SPY) · Neoplasms
  15. Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Babiker H, Brana I, Mahadevan D, et al. · Oncologist · 2021 · Derived
    PubMed: PMID 33942954 · NCT02383212
  16. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.
    Reck M, Rodríguez-Abreu D, Robinson AG, et al. · J Clin Oncol · 2021 · Background
    PubMed: PMID 33872070 · NCT06865339 (TRIPL)
  17. Phase 2 study of pembrolizumab in patients with advanced rare cancers.
    Naing A, Meric-Bernstam F, Stephen B, et al. · J Immunother Cancer · 2021 · Background
    PubMed: PMID 32188704 · NCT07085572 (INTERVAL) · Adrenocortical Carcinoma
  18. Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies.
    McGregor BA, Campbell MT, Xie W, et al. · Cancer · 2021 · Background
    PubMed: PMID 33216356 · NCT07085572 (INTERVAL) · Adrenocortical Carcinoma
  19. Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538.
    Klein O, Senko C, Carlino MS, et al. · Oncoimmunology · 2021 · Background
    PubMed: PMID 33889439 · NCT07085572 (INTERVAL) · Adrenocortical Carcinoma
  20. The long and winding road to effective immunotherapy in patients with adrenocortical carcinoma.
    Grisanti S, Cosentini D, Laganà M, et al. · Future Oncol · 2021 · Background
    PubMed: PMID 32857613 · NCT07085572 (INTERVAL) · Adrenocortical Carcinoma
  21. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Fassnacht M, Assie G, Baudin E, et al. · Ann Oncol · 2021 · Background
    PubMed: PMID 32861807 · NCT07085572 (INTERVAL) · Adrenocortical Carcinoma
  22. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.
    Cascone T, William WN, Weissferdt A, et al. · Nat Med · 2021 · Background
    PubMed: PMID 33603241 · NCT06865339 (TRIPL)
  23. Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma.
    Bedrose S, Miller KC, Altameemi L, et al. · J Immunother Cancer · 2021 · Background
    PubMed: PMID 32737143 · NCT07085572 (INTERVAL) · Adrenocortical Carcinoma

2020 (12 papers)

  1. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.
    Migden MR, Khushalani NI, Chang ALS, et al. · Lancet Oncol · 2020 · Derived
    PubMed: PMID 31952975 · NCT02760498
  2. CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma.
    Migden MR, Chandra S, Rabinowits G, et al. · Future Oncol · 2020 · Derived
    PubMed: PMID 31951149 · NCT03836105 (CASE) · Carcinoma, Basal Cell
  3. Rare basal cell metastasis of a basal-squamous skin collision tumour to the lung and axillary lymph node.
    Li R, Lee G, Huang M, et al. · BMJ Case Rep · 2020 · Derived
    PubMed: PMID 31585957 · NCT03132636 · Carcinoma, Basal Cell
  4. Comparison Between 18F-FDG PET-Based and CT-Based Criteria in Non-Small Cell Lung Cancer Patients Treated with Nivolumab.
    Rossi G, Bauckneht M, Genova C, et al. · J Nucl Med · 2020 · Background
    PubMed: PMID 31806768 · NCT06865339 (TRIPL)
  5. PD-1 Blockade in Advanced Adrenocortical Carcinoma.
    Raj N, Zheng Y, Kelly V, et al. · J Clin Oncol · 2020 · Background
    PubMed: PMID 31644329 · NCT07085572 (INTERVAL) · Adrenocortical Carcinoma
  6. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
    Powles T, Park SH, Voog E, et al. · N Engl J Med · 2020 · Background
    PubMed: PMID 32945632 · NCT07085572 (INTERVAL) · Adrenocortical Carcinoma
  7. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
    Herbst RS, Giaccone G, de Marinis F, et al. · N Engl J Med · 2020 · Background
    PubMed: PMID 32997907 · NCT06865339 (TRIPL)
  8. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma.
    Habra MA, Stephen B, Campbell M, et al. · J Immunother Cancer · 2020 · Background
    PubMed: PMID 31533818 · NCT07085572 (INTERVAL) · Adrenocortical Carcinoma
  9. Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III Melanoma.
    Gartrell RD, Marks DK, Rizk EM, et al. · Clin Cancer Res · 2020 · Background
    PubMed: PMID 30647081 · NCT06865339 (TRIPL)
  10. Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma.
    Gartrell-Corrado RD, Chen AX, Rizk EM, et al. · Cancer Res · 2020 · Background
    PubMed: PMID 31948941 · NCT06865339 (TRIPL)
  11. Immunotherapy failure in adrenocortical cancer: where next?
    Cosentini D, Grisanti S, Dalla Volta A, et al. · Endocr Connect · 2020 · Background
    PubMed: PMID 30400026 · NCT07085572 (INTERVAL) · Adrenocortical Carcinoma
  12. Nivolumab in Metastatic Adrenocortical Carcinoma: Results of a Phase 2 Trial.
    Carneiro BA, Konda B, Costa RB, et al. · J Clin Endocrinol Metab · 2020 · Background
    PubMed: PMID 31276163 · NCT07085572 (INTERVAL) · Adrenocortical Carcinoma

2019 (3 papers)

  1. Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial.
    Le Tourneau C, Hoimes C, Zarwan C, et al. · J Immunother Cancer · 2019 · Background
    PubMed: PMID 30348224 · NCT07085572 (INTERVAL) · Adrenocortical Carcinoma
  2. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
    Larkin J, Chiarion-Sileni V, Gonzalez R, et al. · N Engl J Med · 2019 · Background
    PubMed: PMID 31562797 · NCT06865339 (TRIPL)
  3. Quantitative Analysis of Immune Infiltrates in Primary Melanoma.
    Gartrell RD, Marks DK, Hart TD, et al. · Cancer Immunol Res · 2019 · Background
    PubMed: PMID 29467127 · NCT06865339 (TRIPL)

2018 (6 papers)

  1. The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.
    Severson TM, Wolf DM, Yau C, et al. · Breast Cancer Res · 2018 · Derived
    PubMed: PMID 28851423 · NCT01042379 (I-SPY) · Neoplasms
  2. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.
    Migden MR, Rischin D, Schmults CD, et al. · N Engl J Med · 2018 · Derived
    PubMed: PMID 29863979 · NCT02383212
  3. Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810.
    Falchook GS, Leidner R, Stankevich E, et al. · J Immunother Cancer · 2018 · Derived
    PubMed: PMID 27879972 · NCT02383212
  4. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
    Paz-Ares L, Luft A, Vicente D, et al. · N Engl J Med · 2018 · Background
    PubMed: PMID 30280635 · NCT06865339 (TRIPL)
  5. Metabolic activity by 18F-FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC.
    Kaira K, Higuchi T, Naruse I, et al. · Eur J Nucl Med Mol Imaging · 2018 · Background
    PubMed: PMID 28828507 · NCT06865339 (TRIPL)
  6. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
    Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. · N Engl J Med · 2018 · Background
    PubMed: PMID 29658856 · NCT06865339 (TRIPL)

2017 (2 papers)

  1. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.
    Davies MA, Saiag P, Robert C, et al. · Lancet Oncol · 2017 · Trial result
    PubMed: PMID 28592387 · NCT06887088 (ENCEFALO) · Melanoma
  2. Management of Brain Metastases in Patients With Melanoma.
    Chukwueke U, Batchelor T, Brastianos P, et al. · J Oncol Pract · 2017 · Trial result
    PubMed: PMID 27288470 · NCT06887088 (ENCEFALO) · Melanoma

2016 (3 papers)

  1. Systemic therapies for melanoma brain metastases: which drug for whom and when?
    Ramanujam S, Schadendorf D, Long GV, et al. · Chin Clin Oncol · 2016 · Trial result
    PubMed: PMID 26112811 · NCT06887088 (ENCEFALO) · Melanoma
  2. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
    Rugo HS, Olopade OI, DeMichele A, et al. · N Engl J Med · 2016 · Derived
    PubMed: PMID 27406347 · NCT01042379 (I-SPY) · Neoplasms
  3. Adaptive Randomization of Neratinib in Early Breast Cancer.
    Park JW, Liu MC, Yee D, et al. · N Engl J Med · 2016 · Derived
    PubMed: PMID 27406346 · NCT01042379 (I-SPY) · Neoplasms

2013 (1 paper)

  1. Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Berruti A, Baudin E, Gelderblom H, et al. · Ann Oncol · 2013 · Background
    PubMed: PMID 22997446 · NCT07085572 (INTERVAL) · Adrenocortical Carcinoma

2012 (5 papers)

  1. Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial).
    Lin C, Buxton MB, Moore D, et al. · Breast Cancer Res Treat · 2012 · Trial result
    PubMed: PMID 21796368 · NCT01042379 (I-SPY) · Neoplasms
  2. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL.
    Hylton NM, Blume JD, Bernreuter WK, et al. · Radiology · 2012 · Trial result
    PubMed: PMID 22623692 · NCT01042379 (I-SPY) · Neoplasms
  3. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.
    Esserman LJ, Berry DA, DeMichele A, et al. · J Clin Oncol · 2012 · Trial result
    PubMed: PMID 22649152 · NCT01042379 (I-SPY) · Neoplasms
  4. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
    Esserman LJ, Berry DA, Cheang MC, et al. · Breast Cancer Res Treat · 2012 · Trial result
    PubMed: PMID 22198468 · NCT01042379 (I-SPY) · Neoplasms
  5. What is the best way to contour lung tumors on PET scans? Multiobserver validation of a gradient-based method using a NSCLC digital PET phantom.
    Werner-Wasik M, Nelson AD, Choi W, et al. · Int J Radiat Oncol Biol Phys · 2012 · Background
    PubMed: PMID 21531085 · NCT06865339 (TRIPL)

2011 (1 paper)

  1. Accelerating identification and regulatory approval of investigational cancer drugs.
    Esserman LJ, Woodcock J · JAMA · 2011 · Background
    PubMed: PMID 22187281 · NCT01042379 (I-SPY) · Neoplasms

2010 (2 papers)

  1. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients.
    Sperduto PW, Chao ST, Sneed PK, et al. · Int J Radiat Oncol Biol Phys · 2010 · Trial result
    PubMed: PMID 19942357 · NCT06887088 (ENCEFALO) · Melanoma
  2. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.
    Aupérin A, Le Péchoux C, Rolland E, et al. · J Clin Oncol · 2010 · Background
    PubMed: PMID 20351327 · NCT06865339 (TRIPL)

2009 (4 papers)

  1. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.
    Wahl RL, Jacene H, Kasamon Y, et al. · J Nucl Med · 2009 · Background
    PubMed: PMID 19403881 · NCT06865339 (TRIPL)
  2. Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells.
    Grosso JF, Goldberg MV, Getnet D, et al. · J Immunol · 2009 · Background
    PubMed: PMID 19454660 · NCT06865339 (TRIPL)
  3. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
    Eisenhauer EA, Therasse P, Bogaerts J, et al. · Eur J Cancer · 2009 · Background
    PubMed: PMID 19097774 · NCT06865339 (TRIPL)
  4. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy.
    Barker AD, Sigman CC, Kelloff GJ, et al. · Clin Pharmacol Ther · 2009 · Background
    PubMed: PMID 19440188 · NCT01042379 (I-SPY) · Neoplasms

2006 (1 paper)

  1. Long-term follow-up of basal cell carcinomas treated with perilesional interferon alfa 2b as monotherapy.
    Tucker SB, Polasek JW, Perri AJ, et al. · J Am Acad Dermatol · 2006 · Background
    PubMed: PMID 16713458 · NCT05729139 · Carcinoma, Squamous Cell

2005 (1 paper)

  1. Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells.
    Kisielow M, Kisielow J, Capoferri-Sollami G, et al. · Eur J Immunol · 2005 · Background
    PubMed: PMID 15971272 · NCT06865339 (TRIPL)

2004 (1 paper)

  1. Intralesional interferon alpha-2b in the treatment of basal cell carcinoma and squamous cell carcinoma: revisited.
    Kim KH, Yavel RM, Gross VL, et al. · Dermatol Surg · 2004 · Background
    PubMed: PMID 14692941 · NCT05729139 · Carcinoma, Squamous Cell

2002 (1 paper)

  1. Quality of life research within the EORTC-the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer.
    Fayers P, Bottomley A, EORTC Quality of Life Group, et al. · Eur J Cancer · 2002 · Background
    PubMed: PMID 11858978 · NCT06865339 (TRIPL)

2000 (1 paper)

  1. The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy.
    Langendijk H, Aaronson NK, de Jong JM, et al. · Radiother Oncol · 2000 · Background
    PubMed: PMID 10788684 · NCT06865339 (TRIPL)

1992 (1 paper)

  1. Treatment of cutaneous squamous cell carcinomas by intralesional interferon alfa-2b therapy.
    Edwards L, Berman B, Rapini RP, et al. · Arch Dermatol · 1992 · Background
    PubMed: PMID 1444502 · NCT05729139 · Carcinoma, Squamous Cell

1990 (1 paper)

  1. Intralesional interferon therapy for basal cell carcinoma.
    Cornell RC, Greenway HT, Tucker SB, et al. · J Am Acad Dermatol · 1990 · Background
    PubMed: PMID 2229497 · NCT05729139 · Carcinoma, Squamous Cell

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).